UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Realistic Scepticism: Raymond Aron’s Perspective on the European Construction

Journal of European integration history, 2020, Vol.26 (2), p.267-284

2020

Volltextzugriff (PDF)

Was anybody ever a realist? A sceptical view on the distinction between political realism and liberalism

History of European ideas, 2018-04, Vol.44 (3), p.370-383

2018

Volltextzugriff (PDF)

Pathogenesis of antiphospholipid syndrome: understanding the antibodies

Nature reviews. Rheumatology, 2011-06, Vol.7 (6), p.330-339

2011

Volltextzugriff (PDF)

Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action

British journal of clinical pharmacology, 2022-07, Vol.88 (7), p.3535-3536

2022

Volltextzugriff (PDF)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Targeted oncology, 2022, Vol.17 (1), p.43-51

2022

Volltextzugriff (PDF)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

Targeted oncology, 2020-08, Vol.15 (4), p.449-466

2020

Volltextzugriff (PDF)

Interpretation of Pharmacovigilance Disproportionality Analyses

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.745-746

2023

Volltextzugriff (PDF)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis

BMJ (Online), 2016-05, Vol.353, p.i2231

2016

Volltextzugriff (PDF)

Transparency and robustness of safety signals

BMJ (Online), 2022-11, p.o2588

2022

Volltextzugriff (PDF)

Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?

Rheumatology (Oxford, England), 2024-02, Vol.63 (SI), p.SI4-SI13

2024

Volltextzugriff (PDF)

Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue

Journal of thoracic oncology, 2023-10, Vol.18 (10), p.e112-e113

2023

Volltextzugriff (PDF)

Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY

Immunotherapy, 2023-02, Vol.15 (2), p.85-91

2023

Volltextzugriff (PDF)

Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports: A Note of Caution

Journal of clinical psychopharmacology, 2024-07, Vol.44 (4), p.443-444

2024

Volltextzugriff (PDF)

Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1151-1153

2023

Volltextzugriff (PDF)

New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats

Haematologica (Roma), 2019-04, Vol.104 (4), p.819-826

2019

Volltextzugriff (PDF)

The Approaches to Assess Robustness of Disproportionality Findings in Pharmacovigilance. A Meta-Epidemiological Research

Drug safety, 2022-10, Vol.45 (10), p.1246-1247

2022

Volltextzugriff (PDF)

Antipsychotics and Drug-Induced Liver Injury: Toward Minimum Requirements in Reporting Pharmacovigilance Studies

Journal of clinical psychopharmacology, 2023-01, Vol.43 (1), p.81-83

2023

Volltextzugriff (PDF)

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study

Drug safety, 2023-09, Vol.46 (9), p.857-866

2023

Volltextzugriff (PDF)

Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system

British journal of clinical pharmacology, 2015-08, Vol.80 (2), p.285-293

2015

Volltextzugriff (PDF)

The changing face of drug-induced adrenal insufficiency in the Food and Drug Administration Adverse Event Reporting System

The journal of clinical endocrinology and metabolism, 2022-08, Vol.107 (8), p.e3107-e3114

2022

Volltextzugriff (PDF)

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

Cancers, 2022-09, Vol.14 (19), p.4610

2022

Volltextzugriff (PDF)

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Drug safety, 2022-06, Vol.45 (6), p.663-673

2022

Volltextzugriff (PDF)

Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis

Pharmacological research, 2018-06, Vol.132, p.108-118

2018

Volltextzugriff (PDF)

Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis

Drug safety, 2024-07, Vol.47 (7), p.601-605

2024

Volltextzugriff (PDF)

Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system

Acta diabetologica, 2020, Vol.57 (1), p.71-80

2020

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Realistic Scepticism: Raymond Aron’s Perspective on the European Construction

Was anybody ever a realist? A sceptical view on the distinction between political realism and liberalism

Pathogenesis of antiphospholipid syndrome: understanding the antibodies

Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

Interpretation of Pharmacovigilance Disproportionality Analyses

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis

Transparency and robustness of safety signals

Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?

Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue

Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY

Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports: A Note of Caution

Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats

The Approaches to Assess Robustness of Disproportionality Findings in Pharmacovigilance. A Meta-Epidemiological Research

Antipsychotics and Drug-Induced Liver Injury: Toward Minimum Requirements in Reporting Pharmacovigilance Studies

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study

Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system

The changing face of drug-induced adrenal insufficiency in the Food and Drug Administration Adverse Event Reporting System

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis

Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis

Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system

Suchergebnisse filtern